[Oncolytic virotherapy for human solid tumors]

Area of Science:

• Oncolytic virotherapy
• Molecular oncology
• Gene therapy

Context:

• Cancer development involves telomerase activation, closely linked to human telomerase reverse transcriptase (hTERT) expression.
• Replication-selective, tumor-specific viruses represent a promising therapeutic strategy for neoplastic diseases.
• Adenovirus 5 vectors can be engineered for targeted cancer cell destruction.

Purpose:

• To develop and review telomerase-specific oncolytic adenoviruses for cancer treatment and diagnostics.
• To construct an adenovirus 5 vector (Telomelysin, OBP-301) driven by the hTERT promoter for tumor-specific gene expression.
• To create a modified vector (TelomeScan, OBP-401) with a reporter gene for in vivo viral replication monitoring.

Summary:

• Telomelysin (OBP-301), an attenuated adenovirus 5 vector, efficiently replicates and induces cell killing in human cancer cell lines by leveraging the hTERT promoter.
• Replication and cytotoxicity of Telomelysin are significantly reduced in normal cells lacking telomerase activity, demonstrating tumor specificity.
• TelomeScan (OBP-401), a derivative of OBP-301, incorporates a green fluorescent protein (GFP) gene for visualizing viral replication and has shown potential in detecting metastasis in preclinical models.

Impact:

• Telomerase-specific oncolytic adenoviruses provide a targeted approach to cancer therapy, minimizing damage to healthy tissues.
• The development of TelomeScan allows for non-invasive monitoring of viral activity and tumor spread, aiding in treatment assessment.
• This research highlights advancements in oncolytic virotherapy, combining therapeutic and diagnostic capabilities for improved cancer management.